Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics Closes $110M Series F Funding Round

NEW YORK – Sophia Genetics said Thursday that it has closed a $110 million Series F funding round, led by Israeli venture fund aMoon and Germany-based Hitachi Ventures, with backing from Credit Suisse and the Pictet Group.

Also participating in the round were previous investors Swisscom Ventures, Endeavour Vision, Generation Investment Management, Alychlo, and Eurazeo Growth, plus new investors ACE & Co. and Famille C Invest.

Sophia, which has co-headquarters in Boston and Lausanne, Switzerland, said that it will use the new venture capital to expand further into the US and Asian markets, as well as to improve multimodal capabilities of its technology platform.

"With this new funding round, we can embark on the next stage of our development and take our collaborative approach further, delivering intelligent medicine, together," Sophia Genetics CEO and Founder Jurgi Camblong said in a statement.

"The overall demand for data-driven medicine is rapidly growing, and the next step is to successfully combine multiple sources of data to better address clinicians' needs," added aMoon Partner and CFO Tomer Berkovitz. "With this shift, more complex data will be generated, and we believe that Sophia's decentralized model will play a pivotal role in empowering health organizations to offer better patient care."

The company's last announced funding was a $77 million Series E round that closed in January 2019. To date, Sophia has raised $251 million in private equity.